The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice-Reference-Cited by-同舟云学术

The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice

Published:2024-05-09 Issue:7 Volume: Page:18-25
ISSN:2949-2807
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Rakhimov R. R.¹^ORCID,Sultanbaev A. V.¹^ORCID,Menshikov K. V.²^ORCID,Nasretdinov A. F.¹^ORCID,Musin Sh. I.¹^ORCID,Lipatov O. N.³^ORCID,Suravatkin V. A.¹^ORCID

Affiliation:

1. Republican Clinical Oncological Dispensary, Republic of Bashkortostan

2. Bashkir State Medical University; Republican Clinical Oncological Dispensary, Republic of Bashkortostan

3. Republican Clinical Oncological Dispensary, Republic of Bashkortostan; Bashkir State Medical University

Abstract

Every year, 400,000 new cases of renal cell carcinoma (RCC) and 175,000 deaths are registered worldwide. Currently available advanced treatments for RCC have less toxicity than previously used therapeutic agents, but drug resistance remains a clinically significant problem. Drug resistance occurs as a result of angiogenic transition through activation of pathways that do not depend on VEGF targets of most first-line treatments. Lenvatinib with everolimus can fight resistance to increase both progression-free survival and overall survival in patients with metastatic RCC according to clinical studies.

Publisher

Alfmed LLC

Reference40 articles.

1. Song X.D., Tian Y.N., Li H. et al. Research progress on advanced renal cell carcinoma. J Int Med Res 2020; 48: 300060520924265.

2. Jonasch E NCCN Guidelines updates: management of metastatic kidney cancer. J Natl Compr Canc Netw. 2019; 17:587–589. [PubMed: 31117033]

3. Ellithi M., Elnair R., Chang G.V., Abdallah M.A. Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More. Cureus. 2020 Feb 10;12(2): e6935.

4. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:706–720. [PubMed: 30788497]

5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer. Version 2.2020 https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf; Accessed 8 November 2019.